Stoke Therapeutics, Inc. STOK
We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides ("ASOs") to selectively restore protein levels.
Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with it. There are currently no disease modifying medicines approved for the treatment of Dravet syndrome.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — | — | — | — | — |
| R&D | $137.9M | $89.1M | $82.2M | $77.8M | $54.2M | $32.2M | $23.8M | $8.4M | — |
| SG&A | $67.1M | $48.8M | $41.3M | $38.9M | $31.9M | $20.8M | $11.9M | $4.4M | — |
| Total operating expenses | $205.0M | $137.9M | $123.6M | $116.8M | $86.1M | $53.0M | $35.7M | $12.8M | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M | -$53.0M | -$35.7M | -$12.8M | — |
| Interest expense | $9.0K | $26.0K | $49.0K | — | — | — | — | — | — |
| Pre-tax income | -$6.9M | — | — | — | — | — | — | — | — |
| Income tax | $0 | — | — | — | — | — | — | — | — |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M | -$52.2M | -$32.3M | -$12.5M | — |
| EPS, basic | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | — | — | — | — |
| EPS, diluted | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 | -17.65 | — |
| Shares, diluted (wtd. avg.) | $59.2M | $54.0M | $44.0M | $38.9M | $36.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $84.2M | $128.0M | $191.4M | $113.6M | $144.9M | $287.3M | $222.5M | $105.4M | — |
| Short-term investments | $200.4M | $88.9M | $10.0M | $116.0M | $74.9M | $0 | — | — | — |
| Receivables | $5.9M | $1.7M | — | — | — | — | — | — | — |
| Total current assets | $305.7M | $232.8M | $215.3M | $244.1M | $229.2M | $293.9M | $226.0M | $106.1M | — |
| Property, plant and equipment | $3.1M | $3.9M | $5.8M | $6.7M | $4.1M | $2.7M | $2.5M | $1.2M | — |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M | $297.9M | $228.8M | $107.5M | — |
| Accounts payable | $4.9M | $2.5M | $1.7M | $766.0K | $2.4M | $1.5M | $751.0K | $1.1M | — |
| Total current liabilities | $57.9M | $40.1M | $30.8M | $31.4M | $17.1M | $11.4M | $4.1M | $2.5M | — |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M | $11.8M | $4.3M | $2.5M | — |
| Retained earnings | -$497.7M | -$490.8M | -$401.8M | -$297.1M | -$196.1M | -$110.3M | -$58.0M | -$25.7M | — |
| Total equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M | $286.1M | $224.4M | $105.1M | -$1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M | -$42.2M | -$31.1M | -$11.0M | — |
| Depreciation and amortisation | $1.8M | $2.2M | $2.5M | $1.5M | $974.0K | $888.0K | $450.0K | $214.0K | — |
| Stock-based compensation | $32.2M | $27.5M | $25.3M | $22.9M | $16.4M | $5.8M | $1.9M | $240.0K | — |
| Capital expenditure | $670.0K | $203.0K | $1.6M | $4.0M | $1.2M | $1.1M | $1.6M | $935.0K | — |
| Investing cash flow | -$186.8M | -$107.5M | $105.9M | -$45.9M | -$76.4M | -$1.1M | -$1.6M | -$925.0K | — |
| Financing cash flow | $97.4M | $131.1M | $53.0M | $46.4M | $1.3M | $108.1M | $149.8M | $115.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-170362.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |